Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three ...

Learn how targeted therapy and advanced blood analysis transformed treatment for erthyroderma, a rare inflammatory skin ...

More patients receiving obinutuzumab plus standard therapy versus standard therapy alone had a complete renal response at week 76. HealthDay News — For patients with active lupus nephritis, ...

1 Rheumatology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain 2 Ophthalmology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain Background: Secukinumab is a ...

A significant number of Americans experience chronic inflammatory skin conditions with no pinpointed cause and often no effective treatments beyond symptom management. Now a new study could pave the ...

Generalized pustular psoriasis (GPP) can range in severity and may be life threatening for some people. Treatment typically includes a variety of topical, oral, and injectable medications. General ...

Inpatient dermatologic care costs over $5 billion annually, with significant potential for cost reduction through improved care models. Expanding inpatient dermatology services, including ...

active ingredient secukinumab) biosimilar. Cosentyx is an interleukin (IL)-17A inhibitor developed by the Swiss pharmaceutical company Novartis, used to treat autoimmune diseases such as ...

Background: Anti-interleukin (IL)-23 agents are widely used for autoimmune disease treatment; however, the safety and risks of specific symptoms have not been systematically assessed. Objectives: The ...